Asynchronous delayed Growth Hormone co-secretion in a patient with a macroprolactinoma whilst on dopamine agonist therapy

Maryam Adil, Nijaguna Mathad and Tristan Richardson
Bournemouth Diabetes and Endocrine Centre
www.b-dec.co.uk

Introduction
Co-secretion of growth hormone and prolactin in pituitary adenomas is common. Based on studies, up to 25% growth hormone producing adenomas cosecrete prolactin.1 However, the prevalence of GH secretion among prolactinomas is unknown but thought to be rare.2

We present a case of co-secretion of growth hormone in pituitary macroadenoma with an interesting timeline.

Case History
Mr TL, a 48 year old gentleman, presented originally with a 8mm prolactinoma. He presented with reduced libido for 6 months, and lethargy and retro-orbital headaches for the previous 18-24 months. He had no visual disturbance.

Initial investigations revealed hyperprolactinaemia with a level of over 4000 iu/L and a normal IGF1 of 184 iu/L in the presence of a pituitary macroadenoma (8x11mm, Fig. 1). He responded well to Cabergoline with a noticeable improvement in all his symptoms in conjunction with fall in the prolactin levels to the reference range and reduction in size of macroadenoma.

Prolonged growth hormone-oral glucose tolerance testing showed non-suppression of his growth hormone consistent with Acromegaly. He was initially managed conservatively, but due to persisting symptoms and a consistently raised IGF1, he was treated with pituitary surgery.

Post-surgery(Fig. 2) was associated with a normalisation in Prolactin and IGF1. Histology confirmed co-secretion of Prolactin and GH.

Discussion
Whilst it is well recognised that co-secretion of prolactin and growth hormone can occur in significant number of patients with macroadenomas, it is usually synchronous.

Asynchronous secretion is less common (<2%) and should be monitored and considered with any symptom changes and/or with an annual assessment of IGF1/ Prolactin. It is also more unusual to see growth hormone secretion whilst on treatment with dopamine agonist medications due to the frequently found sensitivity of GH in co-secreting prolactinomas.

References